Article Information
History
- May 5, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Zelalem Temesgen1,*,
- Charles D. Burger2,
- Jason Baker3,
- Christopher Polk4,
- Claudia Libertin5,
- Colleen Kelley6,
- Vincent C. Marconi7,
- Robert Orenstein8,
- Cameron Durrant9,
- Dale Chappell9,
- Omar Ahmed9,
- Gabrielle Chappell9 and
- Andrew D. Badley10
- 1Mayo Clinic, Division of Infectious Disease, Rochester, MN
- 2Mayo Clinic, Division of Pulmonary, Allergy and Sleep Medicine, Jacksonville, FL
- 3Hennepin Healthcare Research Institute, Minneapolis, MN
- 4Atrium Health, Charlotte, NC
- 5Mayo Clinic, Division of Infectious Disease, Jacksonville, FL
- 6Emory University School of Medicine, Division of Infectious Diseases; Special Immunology Service Grady Memorial Hospital, Atlanta, GA
- 7Emory University School of Medicine, Rollins School of Public Health, and Emory Vaccine Center, Division of Infectious Diseases, Atlanta, GA
- 8Mayo Clinic, Division of Infectious Disease, Scottsdale, AZ
- 9Humanigen, Inc., Burlingame, CA
- 10Mayo Clinic, Division of Infectious Disease and Department of Molecular Medicine, Rochester, MN
- ↵*Corresponding author address
Zelalem Temesgen, Mayo Clinic, 200 First ST. SW, Rochester, MN 55901, temesgen.zelalem{at}mayo.edu
Posted May 05, 2021.
LENZILUMAB EFFICACY AND SAFETY IN NEWLY HOSPITALIZED COVID-19 SUBJECTS: RESULTS FROM THE LIVE-AIR PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL
